首页 › 基金 › Fairmount Funds Management LLC › ELVN
Fairmount Funds Management LLC 对 ELVN 的持仓历史
ENLIVEN THERAPEUTICS INC · 医疗保健
Fairmount Funds Management LLC 在 Q3 2026 的 13F 申报中披露持有 ELVN(ENLIVEN THERAPEUTICS INC)1,855,644 股,市值约 US$85.1M,约占其申报组合的 5.33%,在其申报持仓中市值排名第 7 位。 Fairmount Funds Management LLC 最近 13 个申报季度中有 13 个季度披露了 ELVN 持仓,最早可追溯至 Q3 2023。
最后更新: 2026-11-17 · 来源: SEC EDGAR Form 13F-HR
Fairmount Funds Management LLC 对 ELVN 的持仓演变
Fairmount Funds Management LLC 于 Q3 2023 首次披露 ELVN 持仓:2,131,369 股(约 US$29.1M)。 该持仓在 Q2 2026 达到峰值 1,855,644 股,市值约 US$94.2M。 在 13 次申报中,Fairmount Funds Management LLC 2 次增持、1 次减持、9 次保持不变。 最近一期申报(Q3 2026)显示持股 1,855,644 股、市值约 US$85.1M。 持仓曾出现大幅变动:Q1 2024 增持约 50% (随后一个季度股价上涨 33%)、Q1 2026 减持约 50% (随后一个季度股价上涨 29%)。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q3 2023 | 2.13M | $29.11M | 新进 |
| Q4 2023 | 2.13M | $29.50M | 持有 |
| Q1 2024 | 3.20M | $56.34M | 增持 |
| Q2 2024 | 3.20M | $74.85M | 持有 |
| Q3 2024 | 3.20M | $81.80M | 持有 |
| Q4 2024 | 3.20M | $72.06M | 持有 |
| Q1 2025 | 3.20M | $63.03M | 持有 |
| Q2 2025 | 3.71M | $74.45M | 增持 |
| Q3 2025 | 3.71M | $75.97M | 持有 |
| Q4 2025 | 3.71M | $57.16M | 持有 |
| Q1 2026 | 1.86M | $72.74M | 减持 |
| Q2 2026 | 1.86M | $94.17M | 持有 |
| Q3 2026 | 1.86M | $85.06M | 持有 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 ELVN 与 13F 数据
ELVN(ENLIVEN THERAPEUTICS INC)属于医疗保健行业。我们追踪的基金中还有 56 只申报持有 ELVN,申报仓位最大的包括:ORBIMED ADVISORS LLC (US$310.6M), Polar Capital Holdings Plc (US$294.5M), Commodore Capital LP (US$150.1M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 ELVN 的基金
- ORBIMED ADVISORS LLC 6.78M 股 · $310.64M · Q3 2026
- Polar Capital Holdings Plc 6.43M 股 · $294.53M · Q3 2026
- Commodore Capital LP 3.27M 股 · $150.13M · Q3 2026
- Vestal Point Capital, LP 3.23M 股 · $147.83M · Q3 2026
- Siren, L.L.C. 1.48M 股 · $67.62M · Q3 2026
- Bellevue Group AG 1.47M 股 · $67.34M · Q3 2026
- Logos Global Management LP 1.08M 股 · $49.51M · Q3 2026
- First Light Asset Management, LLC 1.02M 股 · $46.68M · Q3 2026
- Novo Holdings A/S 1.00M 股 · $45.84M · Q3 2026
- First Turn Management, LLC 958.70K 股 · $43.95M · Q3 2026
- SAMLYN CAPITAL, LLC 936.17K 股 · $42.91M · Q3 2026
- BAKER BROS. ADVISORS LP 905.19K 股 · $41.49M · Q3 2026
更多关于 Fairmount Funds Management LLC
常见问题
How long has Fairmount Funds Management LLC held ELVN?
Fairmount Funds Management LLC has disclosed ELVN holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Fairmount Funds Management LLC's current position in ELVN?
As of Q3 2026, Fairmount Funds Management LLC holds 1.86M shares of ELVN (ENLIVEN THERAPEUTICS INC), valued at $85.06M, representing 5.33% of its reported portfolio and ranking #7.
Has Fairmount Funds Management LLC been buying or selling ELVN?
In the latest 13F filing (Q3 2026), Fairmount Funds Management LLC held unchanged its position in ELVN. The position peaked in Q2 2026 at 1.86M shares.
Which other funds hold ELVN?
Other major institutional holders of ELVN include ORBIMED ADVISORS LLC, Polar Capital Holdings Plc, Commodore Capital LP, among 56 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.